Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment

Anil K. Jasti, Carlo Selmi, Juan C. Sarmiento-Monroy, Daniel A. Vega, Juan Manuel Anaya, M. Eric Gershwin

Research output: Contribution to journalReview article

Abstract

Introduction: Guillain-Barré syndrome is a rare disease representing the most frequent cause of acute flaccid symmetrical weakness of the limbs and areflexia usually reaching its peak within a month. The etiology and pathogenesis remain largely enigmatic and the syndrome results in death or severe disability in 9–17% of cases despite immunotherapy. Areas covered: In terms of etiology, Guillain-Barré syndrome is linked to Campylobacter infection but less than 0.1% of infections result in the syndrome. In terms of pathogenesis, activated macrophages and T cells and serum antibodies against gangliosides are observed but their significance is unclear. Expert commentary: Guillain-Barré syndrome is a heterogeneous condition with numerous subtypes and recent data point towards the role of ganglioside epitopes by immunohistochemical methods. Ultimately, the syndrome results from a permissive genetic background on which environmental factors, including infections, vaccination and the influence of aging, lead to disease.

Original languageEnglish
Pages (from-to)1175-1189
Number of pages15
JournalExpert Review of Clinical Immunology
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Gangliosides
Therapeutics
Campylobacter Infections
Rare Diseases
Infection
Immunotherapy
Epitopes
Vaccination
Extremities
Macrophages
T-Lymphocytes
Antibodies
Serum
Genetic Background

Keywords

  • autoimmune neuropathy
  • Guillain-Barré
  • immune tolerance
  • infection and immunity
  • Molecular mimicry

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Jasti, A. K., Selmi, C., Sarmiento-Monroy, J. C., Vega, D. A., Anaya, J. M., & Gershwin, M. E. (2016). Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Review of Clinical Immunology, 12(11), 1175-1189. https://doi.org/10.1080/1744666X.2016.1193006

Guillain-Barré syndrome : causes, immunopathogenic mechanisms and treatment. / Jasti, Anil K.; Selmi, Carlo; Sarmiento-Monroy, Juan C.; Vega, Daniel A.; Anaya, Juan Manuel; Gershwin, M. Eric.

In: Expert Review of Clinical Immunology, Vol. 12, No. 11, 01.11.2016, p. 1175-1189.

Research output: Contribution to journalReview article

Jasti, AK, Selmi, C, Sarmiento-Monroy, JC, Vega, DA, Anaya, JM & Gershwin, ME 2016, 'Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment', Expert Review of Clinical Immunology, vol. 12, no. 11, pp. 1175-1189. https://doi.org/10.1080/1744666X.2016.1193006
Jasti, Anil K. ; Selmi, Carlo ; Sarmiento-Monroy, Juan C. ; Vega, Daniel A. ; Anaya, Juan Manuel ; Gershwin, M. Eric. / Guillain-Barré syndrome : causes, immunopathogenic mechanisms and treatment. In: Expert Review of Clinical Immunology. 2016 ; Vol. 12, No. 11. pp. 1175-1189.
@article{564b4ab633d34b929f9fa7a3629643a4,
title = "Guillain-Barr{\'e} syndrome: causes, immunopathogenic mechanisms and treatment",
abstract = "Introduction: Guillain-Barr{\'e} syndrome is a rare disease representing the most frequent cause of acute flaccid symmetrical weakness of the limbs and areflexia usually reaching its peak within a month. The etiology and pathogenesis remain largely enigmatic and the syndrome results in death or severe disability in 9–17{\%} of cases despite immunotherapy. Areas covered: In terms of etiology, Guillain-Barr{\'e} syndrome is linked to Campylobacter infection but less than 0.1{\%} of infections result in the syndrome. In terms of pathogenesis, activated macrophages and T cells and serum antibodies against gangliosides are observed but their significance is unclear. Expert commentary: Guillain-Barr{\'e} syndrome is a heterogeneous condition with numerous subtypes and recent data point towards the role of ganglioside epitopes by immunohistochemical methods. Ultimately, the syndrome results from a permissive genetic background on which environmental factors, including infections, vaccination and the influence of aging, lead to disease.",
keywords = "autoimmune neuropathy, Guillain-Barr{\'e}, immune tolerance, infection and immunity, Molecular mimicry",
author = "Jasti, {Anil K.} and Carlo Selmi and Sarmiento-Monroy, {Juan C.} and Vega, {Daniel A.} and Anaya, {Juan Manuel} and Gershwin, {M. Eric}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/1744666X.2016.1193006",
language = "English",
volume = "12",
pages = "1175--1189",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Guillain-Barré syndrome

T2 - causes, immunopathogenic mechanisms and treatment

AU - Jasti, Anil K.

AU - Selmi, Carlo

AU - Sarmiento-Monroy, Juan C.

AU - Vega, Daniel A.

AU - Anaya, Juan Manuel

AU - Gershwin, M. Eric

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Guillain-Barré syndrome is a rare disease representing the most frequent cause of acute flaccid symmetrical weakness of the limbs and areflexia usually reaching its peak within a month. The etiology and pathogenesis remain largely enigmatic and the syndrome results in death or severe disability in 9–17% of cases despite immunotherapy. Areas covered: In terms of etiology, Guillain-Barré syndrome is linked to Campylobacter infection but less than 0.1% of infections result in the syndrome. In terms of pathogenesis, activated macrophages and T cells and serum antibodies against gangliosides are observed but their significance is unclear. Expert commentary: Guillain-Barré syndrome is a heterogeneous condition with numerous subtypes and recent data point towards the role of ganglioside epitopes by immunohistochemical methods. Ultimately, the syndrome results from a permissive genetic background on which environmental factors, including infections, vaccination and the influence of aging, lead to disease.

AB - Introduction: Guillain-Barré syndrome is a rare disease representing the most frequent cause of acute flaccid symmetrical weakness of the limbs and areflexia usually reaching its peak within a month. The etiology and pathogenesis remain largely enigmatic and the syndrome results in death or severe disability in 9–17% of cases despite immunotherapy. Areas covered: In terms of etiology, Guillain-Barré syndrome is linked to Campylobacter infection but less than 0.1% of infections result in the syndrome. In terms of pathogenesis, activated macrophages and T cells and serum antibodies against gangliosides are observed but their significance is unclear. Expert commentary: Guillain-Barré syndrome is a heterogeneous condition with numerous subtypes and recent data point towards the role of ganglioside epitopes by immunohistochemical methods. Ultimately, the syndrome results from a permissive genetic background on which environmental factors, including infections, vaccination and the influence of aging, lead to disease.

KW - autoimmune neuropathy

KW - Guillain-Barré

KW - immune tolerance

KW - infection and immunity

KW - Molecular mimicry

UR - http://www.scopus.com/inward/record.url?scp=84992052404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992052404&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2016.1193006

DO - 10.1080/1744666X.2016.1193006

M3 - Review article

AN - SCOPUS:84992052404

VL - 12

SP - 1175

EP - 1189

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 11

ER -